{"entity":{"id":"nct04617522","kind":"trial","name":"Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment","aka":[],"tldr":"An early trial studying the safety and activity of experimental treatment. Its registry status does not establish patient benefit.","summary":"Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment. ClinicalTrials.gov record last updated 2026-06-02: recruiting. Enrollment is planned at 30 participants. Primary completion is estimated at 2026-12. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications.","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT04617522","url":"https://clinicaltrials.gov/study/NCT04617522"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":["trop2"],"drugs":["sacituzumab-govitecan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["ClinicalTrials.gov record last updated 2026-06-02: recruiting. Enrollment is planned at 30 participants. Primary completion is estimated at 2026-12. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications."],"nct":"NCT04617522","phase":"1","setting":"Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment","sponsor":"Gilead Sciences","started":"2021-04-06","startedType":"actual","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04617522/","neighbours":{"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"drug":[{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/"}]}}